TY  - JOUR
AU  - Perna, Laura
AU  - Stocker, Hannah
AU  - Burow, Lena
AU  - Beyer, Léon
AU  - Trares, Kira
AU  - Kurz, Carolin
AU  - Gürsel, Selim
AU  - Holleczek, Bernd
AU  - Tatò, Maia
AU  - Beyreuther, Konrad
AU  - Mons, Ute
AU  - Gerwert, Klaus
AU  - Perneczky, Robert
AU  - Schöttker, Ben
AU  - Brenner, Hermann
TI  - Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study.
JO  - Alzheimer's research & therapy
VL  - 15
IS  - 1
SN  - 1758-9193
CY  - London
PB  - BioMed Central
M1  - DKFZ-2023-02331
SP  - 198
PY  - 2023
N1  - #LA:C070#
AB  - Subjective cognitive complaints (SCC) have been mostly studied in the context of Alzheimer's disease in memory clinic settings. The potential of combining SCC with genetic information and blood biomarkers of neurodegenerative diseases for risk assessment of dementia and depression in the absence of dementia among community-dwelling older adults has so far not been explored.Data were based on a population-based cohort of 6357 participants with a 17-year follow-up (ESTHER study) and a clinic-based cohort of 422 patients. Participants of both cohorts were grouped according to the diagnosis of dementia (yes/no) and the diagnosis of depression in the absence of dementia (yes/no). Participants without dementia included both cognitively unimpaired participants and cognitively impaired participants. Genetic information (APOE ε4 genotype) and blood-based biomarkers of neurodegenerative diseases (glial fibrillary acidic protein; GFAP, neurofilament light chain; NfL, phosphorylated tau181; p-tau181) were available in the ESTHER study and were determined with Simoa Technology in a nested case-control design. Logistic regression models adjusted for relevant confounders were run for the outcomes of all-cause dementia and depression in the absence of dementia.The results showed that persistent SCC were associated both with increased risk of all-cause dementia and of depression without dementia, independently of the diagnostic setting. However, the results for the ESTHER study also showed that the combination of subjective complaints with APOE ε4 and with increased GFAP concentrations in the blood yielded a substantially increased risk of all-cause dementia (OR 5.35; 95
KW  - Humans
KW  - Aged
KW  - Longitudinal Studies
KW  - Neurodegenerative Diseases: diagnosis
KW  - Apolipoprotein E4: genetics
KW  - Alzheimer Disease: diagnosis
KW  - Alzheimer Disease: genetics
KW  - Cohort Studies
KW  - Cognition
KW  - Biomarkers
KW  - tau Proteins: metabolism
KW  - Amyloid beta-Peptides: metabolism
KW  - APOE ε4 (Other)
KW  - Dementia (Other)
KW  - Depression (Other)
KW  - Glial fibrillary acidic protein (Other)
KW  - Older people (Other)
KW  - Subjective cognitive decline (Other)
KW  - Apolipoprotein E4 (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:37951931
C2  - pmc:PMC10638700
DO  - DOI:10.1186/s13195-023-01341-3
UR  - https://inrepo02.dkfz.de/record/285362
ER  -